InjectableLower/Moderate Risk

Boldenone (Equipoise)

Also known as: EQ, Bold, Boldenone Undecylenate, Equipoise

Originally developed as a veterinary compound for horses. A slow-acting injectable known for increasing appetite, vascularity, and red blood cell production. The haematocrit increase is the primary safety concern.

Half-Life

~14 days

Detection

Up to 5 months

Type

Injectable

Risk

Lower/Moderate Risk

What it is

Originally developed as a veterinary compound for horses. A slow-acting injectable with a very long half-life (undecylenate ester). Structurally similar to testosterone but with different properties. Not approved for human use.

What it does

Increases appetite, improves vascularity, and promotes steady lean muscle gains. Often used in longer cycles (16-20 weeks) due to slow onset. Increases red blood cell production (erythropoiesis) more than most other compounds, which can improve endurance but also poses a significant health risk.

Typical dosages

400-600mg per week is commonly reported. Requires long cycles (16-20 weeks minimum) due to the very slow onset of effects. Should be run with a testosterone base. This is not a recommendation; it is what is commonly reported.

These figures reflect commonly reported usage in harm reduction communities. They are not recommendations. There is no safe dose of anabolic steroids for non-medical use. Start low and monitor your health through blood work.

Side effects

  • Elevated red blood cell production (haematocrit rise is the primary concern)
  • Increased appetite
  • Mild androgenic effects (acne, hair loss in predisposed individuals)
  • Anxiety reported by some users
  • Suppression of natural testosterone
  • Mild oestrogen conversion (lower than testosterone)
  • Very long clearance time from the body

Specific risks

  • Haematocrit: the elevated red blood cell production is a serious concern. Haematocrit can rise to dangerous levels, significantly increasing stroke and blood clot risk. Blood work monitoring is essential
  • Cardiovascular: the combination of elevated haematocrit and cholesterol impact increases cardiovascular risk substantially over long cycles
  • Long clearance: the undecylenate ester takes a very long time to clear the body, which extends the period of HPTA suppression and complicates PCT timing
  • Anxiety: some users report significant anxiety on Boldenone, which may be related to its interaction with neurosteroid pathways

What to watch for

  • Haematocrit levels on blood work (above 54% requires immediate action)
  • Headaches or dizziness (can indicate elevated haematocrit)
  • Increased anxiety or restlessness
  • Blood pressure changes
  • Ensure blood work includes a full blood count specifically to monitor red blood cell markers

Other compounds